| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 |
| filingDate |
2000-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2daa97b1b779b5fcf01f63bacc0a156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f91c95c215b652d0dc00318c41671087
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d28f6d9e043de5d8530a9e8f876230c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28c58e0d6f1e8c77bece3bd7fa680c2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e885b3175f1ba80adcb7fe03560fbce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce789b6da2d03e6e5fd0ae299737edc2 |
| publicationDate |
2004-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-517620-A |
| titleOfInvention |
A conjugate comprising a non-peptide moiety, a linking unit and a cytostatic radical |
| abstract |
A conjugate comprises a non-peptide moiety binding to aVb3 or aVb5 integrin (vitronectin) receptors, a linking unit, which can be cleaved enzymatically or hydrolytically with release of the cytotoxic radical or of the radical of a cytostatic or of a cytostatic derivative, and a cytostatic radical or a radical of a cytostatic or of a cytostatic derivative. Preferably the cytostatic radical is camptothecin or 9-aminocamptothecin. The conjugate can be used in the manufacture of a medicament for the treatment of carcinomatous disorders. Also described is process for preparing the conjugates. |
| priorityDate |
1999-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |